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Abstract: Introduction: Toxic mushrooms are distributed across the globe with over 5000 species. Among them, 100
species are responsible for most of the cases of mushroom poisoning. This study aimed to evaluate the epi-
demiologic pattern of mushroom poisoning among patients referred to the main toxicology center of Mashhad
province located in North-east of Iran. Methods: This cross-sectional study was conducted on patients with
final diagnosis of mushroom poisoning referred to the toxicology center of Mashhad, Iran, from February 2005
to 2011. Patients’ demographic characteristics, clinical presentations, laboratory findings, outcomes, and ther-
apeutic measures were collected using a predesigned checklist and searching patient’s profile. Results: 32 cases
with the mean age of 24.6 ± 16.7 years were presented to the toxicology center following mushroom poisoning
(59% female). Mushroom poisoning accounted for 0.1% of all admitted cases. The mean time elapsed from
consumption to referral to poisoning department was 61.9 ± 49.4 hours. 19 (59%) cases were discharged with
complete recovery, 7 (22%) expired, and 6 (19%) cases left hospital against medical advice. Mushroom poisoning
mortality accounted for 1.5% of deceased cases in the studied center. There was significant relationship between
mortality rate and higher values of INR (p = 0.035), PT (p = 0.011) and PTT (p = 0.003). Likewise, there was sig-
nificant relationship between the need for mechanical ventilation and higher values of INR (p = 0.035), PT (p
= 0.006) and PTT (p = 0.014). The relationships between the need for ICU admission, mechanical ventilation,
and mortality rate with the rise of hepatic transaminases and serum bilirubin were not significant. Conclusion:
Based on the findings, the prevalence of mushroom poisoning among patients referred to Mashhad toxicology
center was very low (0.1%), but with a high mortality rate of 22%. Nausea and vomiting were the most common
early symptoms of intoxication and higher values of coagulation profile were correlated with poor outcome.
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1. Introduction
The clinical picture caused by poisonous compounds
in mushrooms is called mushroom poisoning or
"mycetismus"(1). Toxic mushrooms are distributed across
the globe with over 5000 species. Among them, 100 species
are responsible for most of the cases of mushroom poisoning
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(2). Mushroom poisoning is responsible for 50 to 100 deaths
per year in Western Europe. The frequency of mushroom
poisoning is less common in the United States (2). Lethal
dose of alpha-amanitin is reported to be 0.1 mg/kg. A single
specimen of amanita phalloides may contain more than
enough of this constituent to kill a man (3). The time interval
between the ingestion of the mushrooms and the appear-
ance of first symptoms is important for prognosis (1). This
latency period is assessed as an independent prognostic fac-
tor (4). Exposures with late clinical manifestation are more
toxic. Mushrooms with short incubation period (usually
less than 6 hours) contain muscarine, coprin, ibotenic acid
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and psilocybin toxins in which clinical manifestation is mild
and symptoms resolve in shorter period of time (1). Clinical
manifestations following ingestion of toxic mushrooms
are primarily gastrointestinal, which in some cases lead to
hepatic, renal and nervous system damage and even death
after a transient improvement phase (5). The Amatoxin is
responsible for gastrointestinal symptoms as well as hepatic
and renal failure (6). Hepatotoxic mushroom poisoning (due
to Amanita, Lepiota and Galerina species) should be consid-
ered as a medical emergency, since an early diagnosis and
immediate treatment are required for a successful outcome
(5). This study aimed to evaluate the epidemiologic pattern
of mushroom poisoning among patients referred to the main
toxicology center of Mashhad province in North-east of Iran.
2. Methods
2.1. Study design
This retrospective cross-sectional study was designed to
evaluate the epidemiologic pattern of mushroom poisoning
among patients referred to the toxicology center of Mashhad,
Khorasan Razavi province, Iran, from February 2005 to 2011.
All cases of intoxication in this province are referred to the
studied center. The protocol of the study was approved by the
ethic committee of Mashhad University of Medical Sciences
and researchers adhered strictly to the Helsinki declarations
and confidentiality of patients’ information.
2.2. Participants
All patients with final diagnosis of mushroom poisoning were
enrolled using census sampling and without any sex or age
limitation. Diagnosis was made based on history, clinical
manifestation and epidemiologic data. No specific diagnos-
tic laboratory tests were applied, as there were not available.
Latency period was defined as the time duration between the
consumption of mushrooms and initiation of earliest gas-
trointestinal symptoms.
2.3. Data gathering
Patients’ demographic characteristics (sex, age, latency pe-
riod, etc.), clinical presentations, laboratory findings (liver
enzyme, coagulation profile, and bilirubin), outcome (death,
discharge, need for intensive care unit (ICU) admission,
and mechanical ventilation), and therapeutic measures (ac-
tivated charcoal, fluids, penicillin G, and silymarin) were col-
lected using a predesigned checklist and searching patient’s
profile. A trained toxicology resident was responsible for ab-
straction of data from patient’s profile.
2.4. Statistical Analysis
SPSS (Statistical Package for Social Sciences) version 11.5 was
used for statistical analysis. Data were reported as mean and
standard deviation or frequency and percentage. Relation-
ship between mortality rate and level of laboratory measures
was calculated using chi-square or Fisher’s exact tests. A p-
value of less than 0.05 was considered significant.
3. Results:
3.1. Demographic
During the study period, 32 cases with the mean age of 24.6
± 16.7 (range: 6 - 73) years were presented to ED follow-
ing mushroom poisoning (59% female, 62% resided in sub-
urbs). Mushroom poisoning accounted for 0.1% of all admit-
ted cases in the studied center. The mean time elapsed from
consumption to referral to poisoning department was 61.9 ±
49.4 (range: 9 - 168) hours. Table 1 shows the frequency of pa-
tients’ sign and symptom at the admission time. The mean
value of first recorded laboratory measures were as follows:
aspartate aminotransferase (AST) 434 ± 947 (15 - 3812) IU/L,
alanine aminotransferase (ALT) 534 ± 972 (10 - 3426) IU/L,
total bilirubin 4.0 ± 6.3 (0.3 - 27.9) mg/dL, direct bilirubin 1.7
± 2.5 (0.1 - 9.3) mg/dL, prothrombin time (PT) 24.6 ± 24.6
(11.9 - 121.0) seconds, partial thromboplastin time (PTT) 33.8
± 12.5 (19.3 - 72.6) seconds, and international normalized ra-
tio (INR) 2.5 ± 3.6 (0.9 -15.0).
3.2. Treatment
Penicillin G (1million units/Kg/day) and Silymarin (25-50
mg/Kg/day) were administered for 69% and 72% of poisoned
cases, respectively. 25% of patients received activated char-
coal and sorbitol prior to admission to the toxicology center.
3.3. Outcome
19 (59%) cases were discharged with complete recovery, 7
(22%) expired, and 6 (19%) cases left hospital against medical
advice. Mushroom poisoning mortality accounted for 1.5%
of deceased cases in the studied center. There was significant
relationship between mortality rate and higher values of INR
(p = 0.035), PT (p = 0.011) and PTT (p = 0.003). Likewise, there
was significant relationship between the need for mechanical
ventilation and higher values of INR (p = 0.035), PT (p = 0.006)






Loss of consciousness 7 (22)
Epigastric pain 4 (13)
Convulsion 2 (6)
Icter 4 (13)
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and PTT (p = 0.014). There was significant relationship be-
tween the need for ICU admission and higher values of INR
(P< 0.001). The relationships between the need for ICU ad-
mission, mechanical ventilation, and mortality rate with rise
of hepatic transaminases and serum bilirubin were not sig-
nificant.
4. Discussion:
Based on the results of the present study, the prevalence of
mushroom poisoning among patients referred to the main
toxicology center of Mashhad province located in North east
of Iran was very low (0.1%), but with a high mortality rate
of 22%. Nausea and vomiting were the most common early
symptoms of intoxication and higher values of coagulation
profile were correlated with poor outcome. Nearly 10,000
species of mushrooms are identified in the world and ap-
proximately 50-100 species are considered as poisonous (7).
About 90% of mushrooms that involved in exposures could
not be identified (8). Amanita species (including A. phaloids,
A. virosa and A. verna) , Gyromitra esculenta, and the Gale-
rina species are three most common poisonous mushrooms
(9). Amanita grows in many forest cover areas in Iran such as
Mazandaran, Gilan and Azarbaijan (Forest Arasbaran) and is
the most dangerous toxic mushroom in Iran and worldwide
(10). Mushroom poisoning was less frequent in our study in
comparison to a study conducted in Turkey (2). The case-
fatality rate, however, was higher. In Turkish study just 12 out
of 143 patients died due to fulminant hepatic failure. Even
lower mortality rate was reported from Texas (11).In contrast,
much higher mortality rate has been observed from Plovdiv
region of Bulgaria (12). This difference could be attributed to
variation of mushroom species, different amount of ingested
amatoxin or even individual susceptibility (1). Case finding
could also be limited in some areas. Higher case-fatality rate
in this study could be related to limited case reporting ca-
pabilities where just more dramatic cases are being referred.
Despite widespread application of some empiric treatments
including non FDA approved penicillin G, silymarin, no def-
inite treatment has been introduced for mushroom poison-
ing to date (13). In this study, nonspecific antidotes includ-
ing penicillin G, silymarin were administered in majority of
cases in addition to conservative treatments. Penicillin G
displaces amanitin from the binding to plasma protein and
thus promoting its excretion and preventing its hepatic up-
take and also enhances the elimination of the toxin from the
kidneys (14). Although most mushroom poisonings are pre-
sented with gastrointestinal symptoms alone and cases are
usually discharged with recovery, but liver function impair-
ment could happen in some cases and may lead to life threat-
ening consequences (15). Taking the need for mechanical
ventilation, or ICU admission and death as determinants for
poor prognosis in mushroom poisoning, impairment of co-
agulation tests (PT, PTT and INR) represented poor outcome
in this study whereas increased transaminases (AST and ALT)
played no role in prognosis, even though they increased to
more than 10 fold of normal limits. Therefore, ordering of
early and serial coagulation tests is recommended. Consider-
ing high mortality rate, all patients with the history of mush-
room ingestion should be admitted; accordingly treated and
followed up (16). Alpha amanitin levels should be checked
where possible, if amanita poisoning is suspected. If labora-
tory detection of toxin is not available, history of mushroom
ingestion, clinical manifestation and their trends could de-
fine mushroom poisoning (17).
5. Limitations:
As a retrospective investigation, we were required to extract
information from medical records and some necessary data
were not recorded properly.
6. Conclusion:
Based on the results of the present study, the prevalence of
mushroom poisoning among patients referred to the main
toxicology center of Mashhad was very low (0.1%), but with
a high mortality rate of 22%. Nausea and vomiting were the
most common early symptoms of intoxication and higher
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